📄 medicine

Sexual identity as a moderator of associations between lifetime MDMA/ecstasy or psilocybin use and mental health outcomes: An exploratory analysis of a nationally representative sample using NSDUH 2015–2019

This exploratory analysis of nationally representative data found little evidence that sexual identity moderates the associations between lifetime MDMA or psilocybin use and mental health outcomes, with only non-significant-after-correction signals suggesting potential differences in how psilocybin relates to depression for heterosexual versus bisexual individuals.

Original authors: Maya Seale

Published 2026-07-02

📖 4 min read☕ Coffee break read

CC BY 4.0

Original authors: Maya Seale

Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). ✨ This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer

The Big Picture: A National Mood Check

Imagine the United States as a giant classroom of over 200,000 students. Researchers asked them two main things:

Have you ever tried a specific "mind-expanding" drug? (Specifically MDMA/Ecstasy or Psilocybin mushrooms).
How is your mental health? (Are you feeling depressed, suicidal, or just generally stressed?)

Previous studies had found a strange pattern: In the general population, people who had tried these drugs once in their lives often reported better mental health (less depression and suicide thoughts) than those who never tried them. It was like finding that students who had once tasted a specific fruit were less likely to be sad.

The New Question: Does Identity Change the Recipe?

The researchers wanted to know if this "fruit" tasted the same for everyone. Specifically, they looked at sexual identity (Heterosexual, Gay/Lesbian, and Bisexual).

They were testing a theory called "Minorities' Diminished Psychedelic Returns" (MDPR).

The Analogy: Imagine a garden. If you plant a seed (the drug) in rich, safe soil (a supportive environment), it grows into a beautiful flower (good mental health). But if you plant that same seed in rocky, hostile soil (discrimination, stigma, lack of support), it might not grow at all, or it might even wither.
The Theory: The MDPR theory suggests that because marginalized groups (like racial minorities or LGBTQ+ people) often face more stress and less support, the "magic" of these drugs might not work as well for them as it does for privileged groups.

What They Found: The "Bisexual" Signal

The researchers ran the numbers to see if sexual identity changed the results. Here is what happened:

Usage Rates: First, they confirmed that people who identified as Gay/Lesbian or Bisexual were much more likely to have tried these drugs than straight people.
The "Magic" Didn't Work for Everyone: When they looked at the whole group, the "protective" effect of the drugs (less depression/suicide) mostly disappeared when they broke the data down by sexual identity.
The One Oddity (The Bisexual Signal): The only time they saw a difference was with Bisexual people and Psilocybin (mushrooms).
- For Straight people, having tried mushrooms was linked to lower odds of having a severe depressive episode.
- For Bisexual people, that link vanished. Trying mushrooms didn't seem to lower their risk of severe depression.
- Note: The researchers were very careful to say this result was "weak" and might just be a fluke of the data, but it was the only thing that stood out.

Why Might This Be Happening?

The paper suggests a reason based on the "soil" analogy.

Gay and Lesbian people often have strong, established communities where they feel they belong. This might act like a safety net, helping them process their experiences.
Bisexual people, however, often face a unique kind of isolation. They might feel rejected by straight communities and by gay/lesbian communities. They might also hide their identity more to avoid judgment.
The Metaphor: If you are trying to heal with a powerful tool (the drug) but you are doing it alone in the dark because you are afraid to tell anyone who you are, the tool might not work as well. The lack of a "supportive community" might be why the mental health benefits didn't show up for the bisexual group in this study.

The Bottom Line: A "Maybe," Not a "Yes"

The most important thing to understand is that this study did not prove anything for sure.

The "FDR" Check: The researchers ran about 20 different tests. When they applied a strict "math filter" to make sure they weren't just seeing random noise, none of the results survived.
The Conclusion: The data provides very little evidence that sexual identity changes how these drugs affect mental health. The one thing they saw (the bisexual group not getting the same benefit as straight people) is just a hypothesis—a guess for future scientists to test.

In short: The study suggests that for sexual minorities, the "magic" of these drugs might depend heavily on whether they have a safe, supportive community to help them through the experience. Without that support (which bisexual people often lack more than others), the benefits might not appear. However, because the data wasn't strong enough to be 100% sure, this is just a starting point for more research, not a final answer.

Technical Summary: Sexual Identity as a Moderator of Associations Between Lifetime MDMA/Ecstasy or Psilocybin Use and Mental Health Outcomes

Problem Statement
While prior population-level research indicates that lifetime use of MDMA/ecstasy and psilocybin is associated with reduced odds of psychological distress, suicidality, and major depressive episodes (MDE), these associations may not be uniform across all demographic groups. Building on the "Minorities' Diminished Psychedelic Returns" (MDPR) framework, which posits that structural inequality and suboptimal "set and setting" conditions limit health benefits for marginalized racial and ethnic groups, this study investigates whether sexual identity similarly moderates these associations. Specifically, the study addresses calls to disaggregate sexual minority data (separating bisexual from lesbian/gay respondents) to determine if the protective effects of psychedelics vary by sexual orientation, particularly given the elevated mental health disparities and unique minority stressors (e.g., biphobia, identity concealment) faced by sexual minorities.

Methodology
This study employed a cross-sectional secondary analysis of pooled data from the National Survey on Drug Use and Health (NSDUH) covering the years 2015–2019. The final sample consisted of 210,392 U.S. adults (195,385 heterosexual, 10,367 bisexual, and 4,640 lesbian/gay).

Design: A two-step exploratory design was utilized.
1. Full-Sample Interaction Screen: Survey-weighted multivariable logistic regressions tested interaction terms between sexual identity (heterosexual, bisexual, lesbian/gay) and lifetime use of MDMA/ecstasy or psilocybin across six mental health outcomes.
2. Subgroup Modeling: Stratified models were estimated only for substance–outcome combinations that yielded significant interactions ( $p \le .05$ ) in the first step.
Variables:
- Independent Variables: Lifetime MDMA/ecstasy use and lifetime psilocybin use (binary).
- Dependent Variables: Past-month serious psychological distress (SPD), past-year suicidal ideation, past-year suicidal planning, lifetime MDE, past-year MDE, and severe past-year MDE.
- Covariates: Race, sex, age, education, income, marital status, risky behavior engagement, and lifetime use of various other substances (including LSD, cocaine, marijuana, ketamine, and poppers).
Statistical Analysis: Analyses were conducted using the R survey package to account for the complex clustered and stratified design of NSDUH. A Benjamini–Hochberg False Discovery Rate (FDR) correction was applied to the interaction screen results to control for multiple testing.

Key Results

Prevalence: Lifetime MDMA/ecstasy and psilocybin use were significantly more common among bisexual and lesbian/gay respondents compared to heterosexual respondents. Bisexual respondents reported the highest prevalence of use for both substances.
Interaction Screening: In the full-sample interaction screen, only two terms met the nominal significance threshold ( $p \le .05$ $p \leq .05$ ), both involving bisexual identity and psilocybin:
- Interaction with past-year suicidal ideation ( $p = .03579$ ).
- Interaction with severe past-year MDE ( $p = .04950$ ).
- No significant interactions were found for lesbian/gay identity or for MDMA/ecstasy use.
- Crucially, neither of these nominally significant interactions survived the Benjamini–Hochberg FDR correction (the rank-1 critical value was .0025).
Subgroup Models:
- Among heterosexual respondents, lifetime psilocybin use was associated with reduced odds of severe past-year MDE (adjusted Odds Ratio [aOR] = 0.85, $p = .03170$ ).
- Among bisexual respondents, no significant association was found between psilocybin use and severe past-year MDE or suicidal ideation.
- Lesbian/gay estimates were non-significant and, in the case of severe MDE, trended in the opposite direction (aOR = 1.59), though the confidence interval was wide.

Key Contributions

Extension of MDPR Framework: This study is the first to explicitly test the MDPR framework against sexual identity, moving beyond the previously established race/ethnicity moderation found by Jones and Nock.
Disaggregation of Sexual Minorities: By analyzing bisexual and lesbian/gay respondents separately, the study highlights that mental health outcomes and substance-use associations may differ significantly within the LGBTQ+ population, supporting calls to avoid aggregating these groups in public health research.
Hypothesis Generation: The study identifies specific, albeit non-significant after correction, signals suggesting that the protective association of psilocybin with severe MDE observed in heterosexual populations may not extend to bisexual populations.

Significance and Claims
The paper concludes that the data provides little to no support for a broad "Minors' Diminished Psychedelic Returns" pattern across sexual identity, as most interaction terms were null and none survived FDR correction. The authors characterize the findings as hypothesis-generating rather than confirmatory.

The modest significance of the results suggests that:

The protective mental health associations of psychedelics may not be uniform across sexual identities.
The specific lack of association for bisexual respondents (compared to the protective effect seen in heterosexuals) may be driven by bisexual-specific minority stressors, such as lower community belonging, higher rates of identity concealment, and biphobia, which could impede the "integration" and social safety required for psychedelic benefits.
Future research and clinical trials (Psychedelic-Assisted Therapy) should consider sexual identity as a distinct variable, particularly for bisexual individuals, and investigate whether social support and integration resources mediate these outcomes.

The authors explicitly caution against causal inference due to the cross-sectional nature of the data and note that unmeasured confounders (e.g., context of use, trauma history) cannot be ruled out.